CardiologyManagement

AFib Anticoagulation Decision (ESC 2024)

AFib Anticoagulation Decision (ESC 2024): AFib - Anticoagulation Decision → Valvular AFib? → WARFARIN ONLY.

Pathway Overview

11 steps

Algorithm Steps

11 total

01Start
AFib - Anticoagulation Decision
Non-valvular atrial fibrillation
02Decision
Valvular AFib?
Mechanical valve or mod-severe MS
If Yes
1. 03Warning
  WARFARIN ONLY
  DOACs contraindicated
  Mechanical heart valve
  Moderate-severe mitral stenosis
  Target INR per valve type
If No
1. 04Action
  Calculate Stroke Risk
  CHA₂DS₂-VA (ESC) or VASc (ACC)
  C: CHF (+1)
  H: Hypertension (+1)
  A₂: Age ≥75 (+2)
  D: Diabetes (+1)
  S₂: Stroke/TIA (+2)
  V: Vascular disease (+1)
  A: Age 65-74 (+1)
  ESC 2024: Sex no longer scored
2. 05Decision
  Score Result?
3. 06Action
  Score ≥2: Anticoagulate
  Class I recommendation
  DOAC preferred over warfarin
  Strong recommendation
4. 07Action
  DOAC Selection
  Choose based on patient factors
  Apixaban: Best safety profile, renal flexibility
  Rivaroxaban: Once daily, with food
  Edoxaban: After 5-day parenteral
  Dabigatran: Reversible, GI side effects
5. 08Action
  HAS-BLED Assessment
  Identify modifiable bleeding risks
  NOT to withhold anticoagulation
  Modify: HTN, labile INR, drugs, alcohol
  Score ≥3 = high bleeding risk - optimize factors
6. 09Outcome
  Anticoagulation Initiated
  Monitor, reassess annually
7. 10Action
  Score 1: Consider OAC
  Class IIa - Shared decision
  Discuss risk/benefit
  Individual factors matter
  Lean toward anticoagulation
8. Path rejoins step 07Shared downstream outcome
9. 11Action
  Score 0: No OAC
  Not recommended
  Reassess if risk factors develop
  Annual stroke risk <1%

Guideline Source

2024 ESC Guidelines for Atrial Fibrillation + ACC/AHA 2023

DOI: 10.1093/eurheartj/ehae176 View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

Does not address anticoagulation reversal
Drug-drug interactions not covered
Renal dosing adjustments simplified

Contraindicated Populations

pediatricpregnancyvalvular_afib

Applicable Regions

EUUS

EU: ESC 2024: CHA₂DS₂-VA (sex removed as modifier, max 9 points)

US: ACC/AHA 2023: CHA₂DS₂-VASc (includes sex, max 10 points)

Version 1Next review: 2028-09-01

Related Cardiology Pathways

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

CHA₂DS₂-VASc Score

Stroke risk stratification in atrial fibrillation

Open page

Compare

AttendMe.ai vs UpToDate

See how this pathway workflow compares against UpToDate.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical Pathways Clinical Calculators AI Chat with Auto-Detection

Frequently Asked Questions

What is the AFib Anticoagulation Decision (ESC 2024)?

The AFib Anticoagulation Decision (ESC 2024) is a management clinical algorithm for Cardiology. It provides a structured decision tree to guide clinical decision-making, based on 2024 ESC Guidelines for Atrial Fibrillation + ACC/AHA 2023.

What guideline is the AFib Anticoagulation Decision (ESC 2024) based on?

This algorithm is based on 2024 ESC Guidelines for Atrial Fibrillation + ACC/AHA 2023 (DOI: 10.1093/eurheartj/ehae176).

What are the limitations of the AFib Anticoagulation Decision (ESC 2024)?

Known limitations include: Does not address anticoagulation reversal; Drug-drug interactions not covered; Renal dosing adjustments simplified. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the AFib Anticoagulation Decision (ESC 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free

AFib Anticoagulation Decision (ESC 2024)

Algorithm Steps